# Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)

> **NCT02836249** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 181 (actual)

## Conditions studied

- HBV
- Chronic HBV Infection

## Interventions

- **DRUG:** TAF
- **DRUG:** TDF
- **DRUG:** TAF Placebo
- **DRUG:** TDF Placebo

## Key facts

- **NCT ID:** NCT02836249
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-19
- **Primary completion:** 2017-03-21
- **Final completion:** 2023-08-31
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02836249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02836249, "Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02836249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*